Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant, non-lactating women having a diagnosis of Lower Back Pain (LBP) of non-malignant origin present for at least 3 months~* Patients taking analgesic medications for at least 3 months prior to screening and/or dissatisfied with their current therapy~* Patients requiring opioid treatment must be taking daily doses of opioid-based analgesic, equivalent to \< 160 mg of oral morphine~* Baseline score of =5 on an 11-point numerical rater scale, calculated as the average pain intensity during the last 3 days prior to randomization.~Exclusion Criteria:~* History of alcohol and/or drug abuse in Investigator's judgement~* History of significant liver insufficiency~* chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months~* Life-long history of seizure disorder or epilepsy~* History of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated~* Uncontrolled hypertension~* Patients with severely impaired renal function~* Patients with moderate to severly impaired hepatic function or with laboratory values reflecting inadequate hepatic function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
- 002 (Type: ACTIVE_COMPARATOR): oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
- 003 (Type: PLACEBO_COMPARATOR): placebo matching placebo twice daily for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).